Ensysce Biosciences Inc reports results for the quarter ended in June - Earnings Summary

Ensysce Biosciences

11/08/2023 14:45

* Ensysce Biosciences Inc  ENSC.OQ  reported a quarterly
adjusted
loss of 98 cents​​ per share for the quarter ended in June. The
mean expectation of three analysts for the quarter was for a
loss of $2.73 per share.
    * Revenue rose 136.2% to $490.00 thousand from a year ago;
analysts expected $826.67 thousand. 
    * Ensysce Biosciences Inc's reported EPS for the quarter was
a
loss of 98 cents​.
    * The mean earnings estimate of analysts had risen by
about 75.1%
in the last three months.​ 
    * In the last 30 days, there have been no earnings estimate
revisions by analysts covering the company. 
    * Ensysce Biosciences Inc shares had risen by 8.9% this
quarter and lost 78.2% so far this year.
    * The company reported a quarterly loss of $2.24 million.
    * Wall Street's median 12-month price target for Ensysce
Biosciences Inc is $16.33 
    * The current average analyst rating on the shares is "buy"
and
the breakdown of recommendations is 1 "strong buy" or "buy," no
"hold" and no "sell" or "strong sell." 

This summary was machine generated from LSEG Refinitiv data
August 11 at 01:45 p.m. UTC. ​All figures in US dollars unless
otherwise stated. QUARTER ENDING    ESTIMATE       ACTUAL         BEAT, MET,
                                                 MISSED
 Jun. 30 2023      -2.73          -0.98          Beat
 Mar. 31 2023      -5.08          -2.08          Beat
 Dec. 31 2022      -28.88         -18.24         Beat
 Sep. 30 2022      -38.40         -8.88          Beat